Skip to main content

Advertisement

Table 1 Baseline patient characteristics

From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Patient characteristics Patients (n = 65)
Median age, years (range) 51 (18–84)
Age group, n (%)
  < 60 years 48 (73.8)
  ≥ 60 years 17 (26.2)
Sex, n (%)
 Male 34 (52.3)
 Female 31 (47.7)
Disease, n (%)
 AML 33 (50.8)
  De novo AML 23 (35.4)
  Secondary AMLa 10 (15.4)
 ALL 31 (47.7)
  Philadelphia-positive 3 (4.6)
  Philadelphia-negative 28 (43.1)
 ABL 1 (1.5)
Risk group, n (%) [1, 36]
 Favorable 3 (4.6)
 Intermediate 29 (44.6)
 Poor 30 (46.2)
 Unknown 3 (4.6)
Risk group (AML only), n (%) [1]
 Favorable 3 (9.1)
 Intermediate 16 (48.5)
 Poor 12 (36.4)
 Unknown 2 (6.0)
Induction chemotherapy, n (%)
 AID-based regimen 30 (46.2)
 Modified FLAI 3 (4.6)
 VPD-based regimen 30 (46.2)
 ADVP-based regimen 2 (3.1)
Median BM blast percentage at diagnosis (range) 80.0 (12.9–98.5)
Median duration of micafungin treatment, days (range) 24 (1–68)
Median time from induction chemotherapy to severe neutropenia (ANC < 500/μL), days (range) 24 (11–84)
  1. Abbreviations: AML Acute myeloid leukemia, ALL Acute lymphoblastic leukemia, ABL Acute biphenotypic leukemia, AID Cytarabine + idarubicin, FLAI Fludarabine + cytarabine + idarubicin, VPD Vincristine + prednisolone + daunorubicin, ADVP Cytarabine + daunorubicin + vincristine + prednisolone, BM Bone marrow, ANC Absolute neutrophil count; aSecondary AML (10) included AML transformation from myelodysplastic syndrome (8), AML transformation from chronic myelomonocytic leukemia (1) and treatment-related AML (1)